Cholesterol Lowering Drug Market is estimated to be US$ 18.7 billion by 2030 with a CAGR of 7.5% during the forecast period

Download Sample

Published Date: May 2023

The Cholesterol Lowering Drug Market accounted for US$ 8.8 billion in 2020 and is estimated to be US$ 18.7 billion by 2029 and is anticipated to register a CAGR of 7.5%. High cholesterol levels have been associated with cardiovascular disease. There are various forms of statins, some of which include atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin. Bile acid sequestrants can be difficult to use as they decrease the absorption of multiple drugs, may increase triglyceride levels, and cause constipation and other GI side effects. PCSK9 inhibitors are very useful when maximally tolerated statin therapy does not reduce LDL sufficiently and in statin intolerant patients. PCSK9 inhibitors have very few side effects.

The report "Global Cholesterol Lowering Drug Market, By Drug Class (Statins & Combination, PCSK9 Inhibitors, Bile Acid Sequestrants, Fibrates, Cholesterol Absorption Inhibitors and Others), By Indication (Hypercholesterolemia, Coronary Artery Disease, Higher Triglycerides), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030”

Key Highlights:

On 28^th March 2020, Inclisiran, an investigational cholesterol-lowering treatment, was added to the pipeline from the Novartis acquisition of The Medicines Company. Inclisiran will potentially be the first and only LDL-C lowering siRNA treatment.
On 1^st dec 2020, AstraZeneca announced that it has agreed to sell the rights to Crestor (rosuvastatin) and its associated medicines in more than 30 countries in Europe (with the exception of the UK and Spain) to Grünenthal, a German pharmaceutical company.

Analyst View:

Increasing incidence of Coronary Artery diseases drives the market of cholesterol lowering drug. For Instance, Overall, raised cholesterol is estimated to cause 2.6 million deaths (4.5% of total) and 29.7 million DALYS, or 2% of total DALYS. Raised total cholesterol is a major cause of disease burden in both the developed and developing world as a risk factor for ischemic heart disease and stroke. New drug formulation also drives the market. For instance, Top medical innovations in the cholesterol lowering drugs market primarily involve bempedoic acid in drug formulations and apart from North America and Europe, manufacturers are leveraging opportunities in Asia Pacific, since governments of rapidly developing countries are increasingly investing toward the strengthening of their healthcare infrastructure.

Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “Global Cholesterol Lowering Drug Market, By Drug Class (Statins & Combination, PCSK9 Inhibitors, Bile Acid Sequestrants, Fibrates, Cholesterol Absorption Inhibitors and Others), By Indication (Hypercholesterolemia, Coronary Artery Disease, Higher Triglycerides), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030”

Key Market Insights from the report:

The Global Cholesterol Lowering Drug Market accounted for US$ 8.8 billion in 2020 and is estimated to be US$ 18.7 billion by 2029 and is anticipated to register a CAGR of 7.5%. The Global Cholesterol Lowering Drug Market is segmented based on the Drug Class, Indication, Distribution Channel and region.

By Drug Class, the Global Cholesterol Lowering Drug Market is segmented into Statin & Combination, PCSK9 Inhibitors, Bile Acid Sequestrants, Fibrates, Cholesterol Absorption Inhibitors and Others.
By Indication, the target market is segmented into Hypercholesterolemia, Coronary Artery Disease, and Higher Triglycerides.
By Distribution Channel, the target market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies.
By region, the Global Cholesterol Lowering Drug Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the worldwide leader in the sepsis diagnostics market in terms of revenue, due to the developed healthcare system and health awareness among people.

Competitive Landscape:

The key players operating in the Global Cholesterol Lowering Drug Market includes Sanofi, Pfizer, Inc., GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc., Amgen Inc., Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd. and AbbVie, Inc.

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.

About Prophecy Market Insights

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Some Important Points Answered in this Market Report Are Given Below:

Explains an overview of the product portfolio, including product development, planning, and positioning.
Explains details about key operational strategies with a focus on R&D strategies, corporate structure, localization strategies, production capabilities, and financial performance of various companies.
Detailed analysis of the market revenue over the forecasted period.
Examining various outlooks of the market with the help of Porter’s five forces analysis, PEST & SWOT Analysis.
Study on the segments that are anticipated to dominate the market.
Study on the regional analysis that is expected to register the highest growth over the forecast period.